HomeCompareEVSM vs JNJ

EVSM vs JNJ: Dividend Comparison 2026

EVSM yields 3.04% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $6.2K in total portfolio value· pulled ahead in Year 8
10 years
EVSM
EVSM
● Live price
3.04%
Share price
$50.19
Annual div
$1.53
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$369.85
Full EVSM calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — EVSM vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVSMJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVSM + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVSM pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVSM
Annual income on $10K today (after 15% tax)
$258.45/yr
After 10yr DRIP, annual income (after tax)
$314.37/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $3,723.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVSM + JNJ for your $10,000?

EVSM: 50%JNJ: 50%
100% JNJ50/50100% EVSM
Portfolio after 10yr
$27.4K
Annual income
$2,559.87/yr
Blended yield
9.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EVSM
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVSM buys
0
JNJ buys
0
No recent congressional trades found for EVSM or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVSMJNJ
Forward yield3.04%2.14%
Annual dividend / share$1.53$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$24.3K$30.5K
Annual income after 10y$369.85$4,749.88
Total dividends collected$3.4K$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EVSM vs JNJ ($10,000, DRIP)

YearEVSM PortfolioEVSM Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,004$304.06$10,594$274.49+$410.00EVSM
2$12,087$312.70$11,294$360.69+$793.00EVSM
3$13,254$321.00$12,133$476.91+$1.1KEVSM
4$14,511$328.97$13,156$635.42+$1.4KEVSM
5$15,863$336.60$14,432$854.61+$1.4KEVSM
6$17,318$343.90$16,056$1,162.76+$1.3KEVSM
7$18,881$350.87$18,175$1,604.53+$706.00EVSM
8← crossover$20,560$357.51$21,009$2,252.68$449.00JNJ
9$22,363$363.84$24,911$3,229.73$2.5KJNJ
10$24,298$369.85$30,458$4,749.88$6.2KJNJ

EVSM vs JNJ: Complete Analysis 2026

EVSMStock

EVSM is actively managed to invest in tax-exempt municipal securities. The fund will normally invest in municipal obligations rated investment grade, and will aim to maintain a dollar-weighted average portfolio duration of less than three years, but may invest in individual securities of any maturity. In selecting securities, the adviser primarily looks at the issuers creditworthiness and the relative value of the obligation in the market. ESG factors are also considered. As an actively managed fund, the fund may periodically allocate some funds to those subject to regular federal income tax and junk bonds.

Full EVSM Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EVSM vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVSM vs SCHDEVSM vs JEPIEVSM vs OEVSM vs KOEVSM vs MAINEVSM vs ABBVEVSM vs MRKEVSM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.